Omecamtiv mecarbil is a first in class direct activator of cardiac myosin, the motor protein that causes cardiac contraction. It is being evaluated as a potential treatment of heart failure in both intravenous and oral formulations with the goal of establishing a new continuum of care for patients in both the in-hospital and outpatient settings. Clinical trials providing an I.V. delivery of omecamtiv mecarbil have shown that plasma levels of the drug can be delivered safely and effectively. However, standard release formulations and some extended release formulations gave peak to trough ratios that may be too great to provide a safe and effective amount of omecamtiv mecarbil to patients who need the drug in a chronic or preventative setting Accordingly, an effective sustained release formulation would be desirable for increased patient safety and effectiveness. In one aspect, there is provided a pharmaceutical formulation comprising: omecamtiv mecarbil dihydrochloride hydrate； a control release agent； a pH modifying agent selected from the group comprising maleic acid, fumaric acid, tartaric acid, and glutamic acid, and any combination thereof； a filler； and a lubricant.
